RU2012105641A - Фолатнацеленные диагностические средства и лечение - Google Patents

Фолатнацеленные диагностические средства и лечение Download PDF

Info

Publication number
RU2012105641A
RU2012105641A RU2012105641/15A RU2012105641A RU2012105641A RU 2012105641 A RU2012105641 A RU 2012105641A RU 2012105641/15 A RU2012105641/15 A RU 2012105641/15A RU 2012105641 A RU2012105641 A RU 2012105641A RU 2012105641 A RU2012105641 A RU 2012105641A
Authority
RU
Russia
Prior art keywords
tumor
patient
administering
folate receptors
clinical benefit
Prior art date
Application number
RU2012105641/15A
Other languages
English (en)
Russian (ru)
Inventor
Кристофер Пол Лимон
Ричард МЕССМЭНН
Дэвид МОРГЕНСТЕРН
Original Assignee
Индосайт, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Индосайт, Инк. filed Critical Индосайт, Инк.
Publication of RU2012105641A publication Critical patent/RU2012105641A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G01N33/5752—
    • G01N33/57545—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012105641/15A 2009-07-31 2010-07-30 Фолатнацеленные диагностические средства и лечение RU2012105641A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23059509P 2009-07-31 2009-07-31
US61/230,595 2009-07-31
US34644410P 2010-05-19 2010-05-19
US61/346,444 2010-05-19
US35102210P 2010-06-03 2010-06-03
US61/351,022 2010-06-03
PCT/US2010/043992 WO2011014821A1 (en) 2009-07-31 2010-07-30 Folate-targeted diagnostics and treatment

Publications (1)

Publication Number Publication Date
RU2012105641A true RU2012105641A (ru) 2013-09-10

Family

ID=43529728

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012105641/15A RU2012105641A (ru) 2009-07-31 2010-07-30 Фолатнацеленные диагностические средства и лечение

Country Status (13)

Country Link
US (2) US20120128587A1 (show.php)
EP (1) EP2460013A4 (show.php)
JP (1) JP2013501224A (show.php)
KR (1) KR20120050462A (show.php)
CN (2) CN104857534A (show.php)
AU (1) AU2010278734A1 (show.php)
BR (1) BR112012002064A2 (show.php)
CA (1) CA2769754A1 (show.php)
IL (1) IL217744A0 (show.php)
IN (1) IN2012DN01708A (show.php)
NZ (1) NZ598145A (show.php)
RU (1) RU2012105641A (show.php)
WO (1) WO2011014821A1 (show.php)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2187965T1 (sl) 2007-08-17 2020-03-31 Purdue Research Foundation Office Of Technology Commercialization Konjugati vezalca ligand-veznika PSMA in metode za uporabo
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2638395A4 (en) 2010-11-12 2016-06-01 Endocyte Inc METHOD FOR TREATING CARCINOMA
WO2012142281A1 (en) * 2011-04-12 2012-10-18 Endocyte, Inc. Solid pharmaceutical composition
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
EP3057619A1 (en) 2013-10-16 2016-08-24 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
GEP20237497B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287731A1 (en) 2013-11-14 2016-10-06 Endocyte, Inc. Compounds for Positron Emission Tomography
EP3071971B1 (en) 2013-11-19 2019-04-24 Purdue Research Foundation Patient selection method for inflammation
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CN107427009A (zh) * 2015-01-11 2017-12-01 恩多塞特公司 癌症成像剂
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
WO2018182776A1 (en) * 2016-03-29 2018-10-04 Endocyte, Inc. Folate conjugate for use in targeting tumor associated macrophages
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
EP3463367A4 (en) * 2016-05-25 2020-01-29 Purdue Research Foundation METHOD OF TREATING CANCER BY TARGETING SUPPRESSIVE CELLS OF MYELOID ORIGIN
JP2021522193A (ja) 2018-04-17 2021-08-30 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 癌を治療する方法
US12473265B2 (en) 2019-05-20 2025-11-18 Endocyte, Inc. Methods for preparing PSMA conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2517729A3 (en) * 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
EP1827501B2 (en) * 2004-12-21 2013-11-20 Nektar Therapeutics Stabilized polymeric thiol reagents
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
CN101175757B (zh) * 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
DE602006012816D1 (de) * 2005-03-30 2010-04-22 Endocyte Inc Tifizierung von zellulären folat vitamin rezeptoren
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2008051525A2 (en) * 2006-10-25 2008-05-02 Schering Corporation Methods of treating ovarian cancer
CA2690943A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers

Also Published As

Publication number Publication date
KR20120050462A (ko) 2012-05-18
WO2011014821A1 (en) 2011-02-03
CN102549434A (zh) 2012-07-04
IL217744A0 (en) 2012-03-29
NZ598145A (en) 2014-10-31
BR112012002064A2 (pt) 2017-05-09
JP2013501224A (ja) 2013-01-10
US20140140925A1 (en) 2014-05-22
AU2010278734A1 (en) 2012-02-23
CA2769754A1 (en) 2011-02-03
IN2012DN01708A (show.php) 2015-06-05
CN104857534A (zh) 2015-08-26
US20120128587A1 (en) 2012-05-24
EP2460013A4 (en) 2013-04-03
EP2460013A1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
RU2012105641A (ru) Фолатнацеленные диагностические средства и лечение
Wang et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Wick et al. Current status and future directions of anti-angiogenic therapy for gliomas
JP6787792B2 (ja) がんの処置のための併用治療
Mégalizzi et al. 4-IBP, a σ1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs
Infante et al. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours
Spiegelberg et al. The MDM2/MDMX-p53 antagonist PM2 radiosensitizes wild-type p53 tumors
JP2013501224A5 (show.php)
JP7113619B2 (ja) リポソーマルイリノテカンによる乳がんの治療
Isambert et al. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase
Wagner et al. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour
KR20180082428A (ko) 성장 호르몬 결핍의 검출 및 치료
Kaartinen et al. Haemodynamic interactions of medetomidine and the peripheral alpha-2 antagonist MK-467 during step infusions in isoflurane-anaesthetised dogs
Lin et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer
Maino et al. Refill procedures of intrathecal drug delivery systems with a recessed fill port on the pump surface: A prospective comparison study of ultrasound-guided vs. blind refill technique
Su et al. Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles
JP2018538370A (ja) デシタビン、５アザシチジンおよびテトラヒドロウリジンを含有する組成物およびその使用
Yu et al. Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer
Huang et al. Toxic myelitis and arachnoiditis after intrathecal delivery of bupivacaine via an implanted drug delivery system: case report and review of the literature
CN110638802A (zh) Atca在制备治疗肿瘤的药物中的用途
ES3024982T3 (en) Injection containing p-boronophenylalanine
Sullivan et al. Treatments for severe psoriasis
Li et al. Pharmacokinetics of Agelastatin A in the central nervous system
Apfelbaum et al. LGG-02. ELUCIDATING THE ROLE OF FGFR1 ALTERATIONS IN PEDIATRIC GLIOMAS
Mohan et al. 67P Efficacy and safety of trastuzumab biosimilar in HER2+ ve metastatic breast cancer: A multicenter phase III study

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160126